Clinical trial
A Phase One, Open Label, Multi-Dose Study to Evaluate the Safety, Tolerability, and Biologic Effects of Three Doses of IW001 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT01199887 is registered in ClinicalTrials.gov with ImmuneWorks as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase One, Open Label, Multi-Dose Study to Evaluate the Safety, Tolerability, and Biologic Effects of Three Doses of IW001 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Lead sponsor
- ImmuneWorks
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- September 30, 2010
- Completion date
- October 31, 2012
- Enrollment
- 30 (actual)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.